These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

120 related articles for article (PubMed ID: 21900726)

  • 1. Selection of an M184V mutation in the cerebrospinal fluid of a treatment-naive HIV-infected individual starting darunavir-based therapy.
    Cornelissen M; Back NK; Burger DM; Blom P; Portegies P; Prins JM; van der Valk M
    Antivir Ther; 2011; 16(6):931-5. PubMed ID: 21900726
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Drug resistance prevalence and HIV-1 variant characterization in the naive and pretreated HIV-1-infected paediatric population in Madrid, Spain.
    de Mulder M; Yebra G; Martín L; Prieto L; Mellado MJ; Rojo P; Muñoz-Fernández MÁ; Jiménez de Ory S; Ramos JT; Holguín A;
    J Antimicrob Chemother; 2011 Oct; 66(10):2362-71. PubMed ID: 21810838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Characterization of drug resistance mutations in naïve and ART-treated patients infected with HIV-1 in Yaounde, Cameroon.
    Ceccarelli L; Salpini R; Moudourou S; Cento V; Santoro MM; Fokam J; Takou D; Nanfack A; Dori L; Torimiro J; Sarmati L; Andreoni M; Perno CF; Colizzi V; Cappelli G
    J Med Virol; 2012 May; 84(5):721-7. PubMed ID: 22431019
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic characterization of HIV-1 strains in Togo reveals a high genetic complexity and genotypic drug-resistance mutations in ARV naive patients.
    Yaotsè DA; Nicole V; Roch NF; Mireille PD; Eric D; Martine P
    Infect Genet Evol; 2009 Jul; 9(4):646-52. PubMed ID: 19460333
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistant minority species are rarely observed in patients on darunavir/ritonavir monotherapy.
    Lambert-Niclot S; Flandre P; Valantin MA; Peytavin G; Sayon S; Morand-Joubert L; Delaugerre C; Algarte-Genin M; Katlama C; Calvez V; Marcelin AG
    J Antimicrob Chemother; 2012 Jun; 67(6):1470-4. PubMed ID: 22396434
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of minority populations of HIV type-1 with K103N and M184V drug resistance mutations among children in Argentina.
    Vignoles M; Barboni G; Agosti MR; Quarleri J; García MK; Ayala SG; Salomón H
    Antivir Ther; 2009; 14(8):1175-81. PubMed ID: 20032547
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment benefit on cerebrospinal fluid HIV-1 levels in the setting of systemic virological suppression and failure.
    Spudich S; Lollo N; Liegler T; Deeks SG; Price RW
    J Infect Dis; 2006 Dec; 194(12):1686-96. PubMed ID: 17109340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical impact of the M184V mutation on switching to didanosine or maintaining lamivudine treatment in nucleoside reverse-transcriptase inhibitor-experienced patients.
    Winters MA; Bosch RJ; Albrecht MA; Katzenstein DA;
    J Infect Dis; 2003 Aug; 188(4):537-40. PubMed ID: 12898440
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HIV-1 pol phylogenetic diversity and antiretroviral resistance mutations in treatment naïve patients from Central West Brazil.
    Cardoso LP; Queiroz BB; Stefani MM
    J Clin Virol; 2009 Oct; 46(2):134-9. PubMed ID: 19682948
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Trends in drug resistance prevalence in HIV-1-infected children in Madrid: 1993 to 2010 analysis.
    de Mulder M; Yebra G; Navas A; Martin L; de Jose MI; Navarro ML; de Ory SJ; Gonzalez-Granado I; Mellado MJ; Ramos JT; Holguin A
    Pediatr Infect Dis J; 2012 Nov; 31(11):e213-21. PubMed ID: 22785049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Co-circulation HIV-1 subtypes B, C, and CRF31_BC in a drug-naïve population from Southernmost Brazil: analysis of primary resistance mutations.
    de Medeiros RM; Junqueira DM; Matte MC; Barcellos NT; Chies JA; Matos Almeida SE
    J Med Virol; 2011 Oct; 83(10):1682-8. PubMed ID: 21837783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Analysis of drug resistance during HIV RNA viraemia in the MONET trial of darunavir/ritonavir monotherapy.
    Pulido F; Arribas JR; Hill A; Van Delft Y; Moecklinghoff C
    Antivir Ther; 2011; 16(1):59-65. PubMed ID: 21311109
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Three-class-resistant human immunodeficiency virus type 1 variant in a drug-naive heterosexual couple.
    Razzolini F; Saladini F; Malincarne L; Vicenti I; Palladino N; Romano L; Francisci D; Zazzi M
    J Clin Microbiol; 2008 Nov; 46(11):3856-9. PubMed ID: 18845824
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Diminished selection for thymidine-analog mutations associated with the presence of M184V in Ethiopian children infected with HIV subtype C receiving lamivudine-containing therapy.
    Averbuch D; Schapiro JM; Lanier ER; Gradstein S; Gottesman G; Kedem E; Einhorn M; Grisaru-Soen G; Ofir M; Engelhard D; Grossman Z
    Pediatr Infect Dis J; 2006 Nov; 25(11):1049-56. PubMed ID: 17072129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Replication capacity, biological phenotype, and drug resistance of HIV strains isolated from patients failing antiretroviral therapy.
    Nicastri E; Sarmati L; d'Ettorre G; Palmisano L; Parisi SG; Uccella I; Rianda A; Concia E; Vullo V; Vella S; Andreoni M
    J Med Virol; 2003 Jan; 69(1):1-6. PubMed ID: 12436471
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of new genotypic cut-off levels to predict the efficacy of lopinavir/ritonavir and darunavir/ritonavir in the TITAN trial.
    Hill A; Marcelin AG; Calvez V
    HIV Med; 2009 Nov; 10(10):620-6. PubMed ID: 19601995
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Genotypic resistance mutations to antiretroviral drugs in newly confirmed human immunodeficiency virus infectors in Beijing].
    Ye JR; Guo L; Lu HY; Xin RL; Zeng Y
    Zhonghua Yi Xue Za Zhi; 2011 Jun; 91(21):1453-6. PubMed ID: 21914279
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Low prevalence of transmitted genetic drug resistance in a cohort of HIV infected naïve patients entering antiretroviral treatment programs at two sites in northern South Africa.
    Nwobegahay J; Selabe G; Ndjeka NO; Manhaeve C; Bessong PO
    J Med Virol; 2012 Dec; 84(12):1839-43. PubMed ID: 23080485
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Human immunodeficiency virus-1 RNA levels in cerebrospinal fluid exhibit a set point in clinically stable patients not receiving antiretroviral therapy.
    Ellis RJ; Childers ME; Zimmerman JD; Frost SD; Deutsch R; McCutchan JA;
    J Infect Dis; 2003 Jun; 187(11):1818-21. PubMed ID: 12751041
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Early virologic nonresponse to tenofovir, abacavir, and lamivudine in HIV-infected antiretroviral-naive subjects.
    Gallant JE; Rodriguez AE; Weinberg WG; Young B; Berger DS; Lim ML; Liao Q; Ross L; Johnson J; Shaefer MS;
    J Infect Dis; 2005 Dec; 192(11):1921-30. PubMed ID: 16267763
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.